Clinical Trial: Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

U.S., Nov. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07223411) titled 'Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma' on Oct. 30.

Brief Summary: This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.

Study Start Date: Nov. 01

Study Type: OBSERVATIONAL

Condition: Locally Advanced Melanoma

Intervention: DRUG: Fianlimab + Cemiplimab

Patients treated with Fianlimab 1600 mg + Cemiplimab 350 mg under protocol ...